Nova Anchora
San Francisco, United States · Founded 2021
- Headquarters
- San Francisco, California
- Founded
- 2021
- Business Model
- B2B
- Website
- novaanchora.com
- Last Round
- SeedApr 2025
- Rounds
- 1
About
Nova Anchora is a biopharmaceutical company advancing a corrective protein therapy for dystrophic epidermolysis bullosa (DEB), a severe rare genetic skin disease. Built on foundational technology developed by Dr. Peter Marinkovich of Stanford Medicine and licensed from Stanford University, the company is developing NvA-011, a recombinant type VII pro-collagen therapy designed for topical application, which received FDA orphan drug designation in 2024.
Summary
Nova Anchora is a Biotech company based in San Francisco, United States, founded in 2021. Its most recent funding was a Seed round in Apr 2025. Investors include Viking Global.
Funding History
Apr 2025
Investors
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/nova-anchora"><img src="https://indexed.vc/api/badge/company/nova-anchora" alt="Nova Anchora on Indexed.vc" width="260" height="76" /></a>